Table 1 |
||
|
Scoring systems for HER2 |
||
|
HER2 IHC Scoring |
||
|
|
||
|
Score |
Pre-ASCO/CAP Scoring Interpretation/Staining pattern |
ASCO/CAP Scoring Interpretation/Staining pattern |
|
0 |
Negative/No staining Staining in < 10% of tumor cells |
Negative/No staining Staining in <10% of tumor cells |
|
1+ |
Negative/Faint/barely perceptible incomplete membrane staining in >10% of tumor cells |
Negative/Faint/barely perceptible incomplete membrane staining in >10% of tumor cells |
|
2+ |
Weakly positive/Weak to moderate complete membrane staining in >10% of tumor cells |
Equivocal/Weak to moderate complete membrane staining in >10% of tumor cells |
|
3+ |
Strongly positive/Strong complete membrane staining in >10% of tumor cells |
Positive/Strong complete membrane staining in >30% of tumor cells |
|
HER2 FISH Scoring |
||
|
|
||
|
Pre-ASCO/CAP Scoring Interpretation/Ratio (HER2/CEP17) |
ASCO/CAP Scoring Interpretation/Ratio (HER2/CEP17) |
|
|
Negative/<2.0 |
Negative/< 1.8 |
|
|
Equivocal/1.8-2.2 |
||
|
Positive/>= 2.0 |
Positive/> 2.2 |
|
|
|
||
|
HER2 human epidermal growth factor receptor 2; IHC immunohistochemistry; FISH fluorescence in situ hybridization; ASCO American Society of Clinical Oncology; CAP College of American Pathologists; CEP17 chromosome enumeration probe 17 (probe for the centromer of chromosome 17) |
||
|
Vogel Diagnostic Pathology 2010 5:50 doi:10.1186/1746-1596-5-50 |
||
